PTGX logo

PROTAGONIST THERAPEUTICS INC

PTGXNASDAQ
🏆 #944 by market capEarnings Nov 4 · PostUS Equity
$340.15▼ $22.45 (−6.60%)
Simulated price
🔔
Track PTGX
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 6.6%
7d▲ 134.6%
14d▲ 137.3%
30d▲ 136.0%
ytd▲ 289.7%
1y▲ 422.6%
🏦Market Cap
$9.07B
Small Cap
📈Revenue Growth (YoY)
-89.4%
Declining
📊Gross Margin
99.9%
High
💵FCF Margin
46.9%
Strong
⚖️P/S Ratio
32.1x
Expensive
Otter Score
72
Fair

Trading Snapshot

Day Range
$338.22 – $346.81
52-Week Range
$62.24 – $160.81
Volume
$1.73B
Avg Volume
$2.26B
Shares Outstanding
64.3M
Next Earnings
Nov 6, 2026

Fundamentals Snapshot

Annual Revenue
$46M
Last Q Revenue
$213M
P/E Ratio
115.7
P/S Ratio
32.1x
EPS (TTM)
$1.26
Dividend Yield
0.00%
Dilution (1yr)
−4.3%

Why Investors Own PTGX

  • ✓High-growth profile — revenue up +17.6% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 67% gross margin and 17% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PTGX logo

PROTAGONIST THERAPEUTICS INC

PTGX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$46M▼ −89.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
97.3%▼ −2.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$158M▼ −162.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$56M▼ −69.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
63.6M▼ −4.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$118M▲ +$32M YoY
StockOtter · stockotter.space

About PROTAGONIST THERAPEUTICS INC

Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
72/100

Analyst Price Target

ⓘ
Average Target
$416.15
▲ +22.3% Upside
High Target$450.56
Low Target$330.12
Based on 18 analysts

Latest News & Updates

🚀
Barron’s·2h ago

PROTAGONIST THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift PTGX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

PROTAGONIST THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.